CA2195531A1 - Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome - Google Patents

Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome

Info

Publication number
CA2195531A1
CA2195531A1 CA002195531A CA2195531A CA2195531A1 CA 2195531 A1 CA2195531 A1 CA 2195531A1 CA 002195531 A CA002195531 A CA 002195531A CA 2195531 A CA2195531 A CA 2195531A CA 2195531 A1 CA2195531 A1 CA 2195531A1
Authority
CA
Canada
Prior art keywords
syt
sequence
ssx2
polypeptide
ssx1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002195531A
Other languages
English (en)
Inventor
Colin Stephen Cooper
Barry Austin Gusterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2195531A1 publication Critical patent/CA2195531A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un procédé visant à diagnostiquer la présence ou l'absence de synoviosarcome et consistant à obtenir un échantillon prélevé dans un tissu d'un patient; mettre l'échantillon en contact avec un élément de liaison spécifique (sbm) qui est spécifique d'un partenaire de liaison (bp), ce dernier étant caractéristique du synoviosarcome, de sorte que la présence de bp dans l'échantillon révèle la présence du synoviosarcome, bp étant absent d'un échantillon équivalent prélevé chez un patient ne souffrant pas de synoviosarcome; et détecter toute liaison de sbm avec son bp. Les caractéristiques des partenaires de liaison du synoviosarcome sont les séquences SSX et SYT et les séquences de fusion de celles-ci. L'invention se rapporte également à des séquences, des réactifs et des procédés thérapeutiques ainsi qu'à des produits pharmaceutiques.
CA002195531A 1994-07-19 1995-07-19 Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome Abandoned CA2195531A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414580.2 1994-07-19
GB9414580A GB9414580D0 (en) 1994-07-19 1994-07-19 Materials and methods relating to the diagnosis of synovial sarcomas

Publications (1)

Publication Number Publication Date
CA2195531A1 true CA2195531A1 (fr) 1996-02-01

Family

ID=10758576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002195531A Abandoned CA2195531A1 (fr) 1994-07-19 1995-07-19 Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome

Country Status (5)

Country Link
EP (1) EP0769053A2 (fr)
AU (1) AU2986595A (fr)
CA (1) CA2195531A1 (fr)
GB (1) GB9414580D0 (fr)
WO (1) WO1996002641A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291658B1 (en) 1997-05-05 2001-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding SSX family members and thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2004020668A2 (fr) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Methode de traitement du synovialome
ATE545658T1 (de) * 2003-07-11 2012-03-15 Oncotherapy Science Inc Verfahren zur behandlung von synovialsarkom
WO2005010190A1 (fr) 2003-07-22 2005-02-03 Ludwig Institute For Cancer Research Peptides ssx-2 presentes par des molecules hla de classe ii
EP2044123B1 (fr) 2006-06-21 2013-03-13 Oncotherapy Science, Inc. Anticorps monoclonaux de ciblage tumoral dirigés contre la fzd10 et leurs utilisations
WO2009018018A2 (fr) * 2007-07-31 2009-02-05 University Of Utah Research Foundation Modèle animal d'un sarcome synovial
CN101970456B (zh) * 2008-01-31 2014-11-26 国立大学法人大阪大学 标签肽及其应用
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
CN110660451B (zh) * 2018-06-13 2023-04-28 广州华大基因医学检验所有限公司 确定生物样本中是否存在融合基因的方法、设备及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084566A (en) * 1987-05-04 1992-01-28 Michael Litt DNA probe which reveals a hypervariable region on human chromosone 1

Also Published As

Publication number Publication date
EP0769053A2 (fr) 1997-04-23
WO1996002641A3 (fr) 1996-03-07
AU2986595A (en) 1996-02-16
WO1996002641A2 (fr) 1996-02-01
GB9414580D0 (en) 1994-09-07

Similar Documents

Publication Publication Date Title
US5633135A (en) Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
US5633136A (en) ALL-1 polynucleotides for leukemia detection and treatment
Turner et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen.
US5571710A (en) CDNA coding for carcinoembryonic antigen
US5352775A (en) APC gene and nucleic acid probes derived therefrom
US6054438A (en) Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
JPH06509701A (ja) ヒト結腸直腸癌において突然変異を起こしている遺伝子
US5658784A (en) Nucleic acid encoding transcription factor p300 and uses of p300
US5227292A (en) Neurofibromatosis type 1 gene
CA2195531A1 (fr) Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome
US5986078A (en) DNA sequence encoding the tumor suppressor gene ING1
AU664535B2 (en) Novel T-cell lymphoma cDNA clones
EP0263933B1 (fr) cADN codant pour l'antigène carcinoembryonnaire
US6586577B2 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
US6077685A (en) Tumor suppressor merlin and antibodies thereof
Mangelsdorf et al. Immunoselection of cDNAs to avian intestinal calcium binding protein 28K and a novel calmodulin-like protein: assessment of mRNA regulation by the vitamin D hormone
Mishra et al. The human actin-regulatory protein cap G: gene structure and chromosome location
WO2003007793A2 (fr) Compositions, methodes et trousses de traitement et diagnostic de l'hypertension
US5231009A (en) Cdnas coding for members of the carcinoembryonic antigen family
US5693778A (en) Arg a human gene related to but distinct from abl proto-oncogene
AU711851B2 (en) Identification of genes altered in multiple myeloma
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
US6747133B1 (en) Antibodies against the tumor suppressor gene ING1
WO2001018037A2 (fr) Proteine induite par p53 avec un domaine de mort pouvant favoriser l'apoptose
WO1997041226A2 (fr) Polynucleotides codant le represseur de transcription gcf2 du recpteur du facteur de croissance epidermique

Legal Events

Date Code Title Description
FZDE Dead